Sandra Grootoonk

Ruhr-Universität Bochum, Bochum, North Rhine-Westphalia, Germany

Are you Sandra Grootoonk?

Claim your profile

Publications (4)2.93 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Theophylline is effective in the treatment of central apneas and periodic breathing. In obstructive sleep apnea syndrome (OSAS), results of pharmacological monotherapy with theophylline are inconsistent. The present study investigates whether additional theophylline in patients with OSAS and continuous positive airway pressure (CPAP) therapy might improve ventilation, lower effective CPAP pressure levels or affect sleep architecture. Patients with mild to moderate OSAS (mean apnea index [AI] 12.8+/-11.7) and CPAP therapy (Autoset system; n=16, all male) received either 900 mg of oral sustained-release theophylline (T) or placebo (P) on two separate nights, 3 days apart, using a randomized double-blind crossover study design. There was no change in AI (T: 0.7+/-1.4 vs. P: 0.7+/-0.6/h; P=0.3) or apnea-hypopnea index (AHI; T: 4.3+/-3.3 vs. P: 4.5+/-3.7/h; P=0.84) when theophylline was added to CPAP therapy. We observed no difference in mean CPAP pressure (T: 6.9+/-2.1 vs. P: 6.7+/-1.9 cm H2O; P=0.7) or 95% pressure percentiles (T: 9.7+/-2.7 vs. P: 9.3+/-2.1cm H2O; P=0.3) when nights with theophylline were compared to placebo nights. Theophylline reduced significantly total sleep time (T: 290.6+/-58.9 vs. P: 338.0+/-40.1 min; P=0.02) and thus sleep efficiency (SE; T: 70.5+/-14.9%, P: 82.0+/-70.5%; P=0.005). Rapid eye movement and slow wave sleep were not affected. Oral theophylline did not show any additional effects on ventilation parameters or pressures in patients with mild to moderate OSAS once CPAP therapy has been successfully installed. SE was reduced with theophylline with unchanged sleep architecture. The role of oral theophylline may be in patients with predominately central apneas not eligible for ventilation therapy or severe cases.
    Respiratory Medicine 05/2005; 99(4):471-6. · 2.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with chronic obstructive pulmonary disease (COPD) may be difficult to stabilize with standard inhaled and oral medication. In those cases, outpatient care may even be impossible. Alternative therapeutic strategies, like subcutaneous self-application of terbutaline, could help to further improve health status. A 42-year old patient with severe COPD was admitted to the hospital. Despite maximal anti-obstructive therapy he required additional intravenous relief therapy and discharge was not possible. We treated this patient with a subcutaneous terbutaline pump for continuous and demand medication. We could show a significant decrease in additional intravenous medication, and the patient could leave the hospital. The use of terbutaline applied by a subcutaneous pump in addition to standard therapy may be helpful in severely ill patients suffering from COPD. This measure increased quality of life and shortened hospital stay.
    Medizinische Klinik 11/2003; 98(10):579-82. · 0.34 Impact Factor
  • Source
    Sandra Grootoonk
    [Show abstract] [Hide abstract]
    ABSTRACT: Problem: Theophyllingabe bei obstruktivem Schlafapnoe-Syndroms (OSAS) ist umstritten. Diese Studie untersucht, ob zur CPAP(continuous positive airway pressure)-Therapie appliziertes Theophyllin bei OSAS-Patienten zu Veränderungen von Ventilation und Schlafarchitektur sowie Reduktion des CPAP-Druckes führt. Methode: In randomisiertem, doppelblinden, placebo-kontrollierten Design erhielten 16 OSAS-Patienten mit CPAP-Therapie oral 900 mg Retard-Theophyllin(T)/Placebo(P) in dreitägigem Abstand. Ergebnis: Für Apnoe-Hypopnoe-Index oder mittleren CPAP-Druck ergab sich zwischen T- und P-Nächten kein Unterschied. Theophyllin reduzierte signifikant Gesamtschlafzeit und Schlafeffizienz (SE). Diskussion: Theophyllin zeigte keine additiven Effekte auf respiratorische Parameter oder CPAP-Druck bei OSAS-Patienten. SE war reduziert bei unveränderter Schlafarchitektur. Wir sehen Theophyllin in der Therapie von zentralen Apnoen, Nicht-Durchführbarkeit einer CPAP-Therapie oder in schwergradigen Fällen.
    http://www-brs.ub.ruhr-uni-bochum.de/netahtml/HSS/Diss/GrootoonkSandra/diss.pdf.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) may be difficult to stabilize with standard inhaled and oral medication. In those cases, outpatient care may even be impossible. Alternative therapeutic strategies, like subcutaneous self-application of terbutaline, could help to further improve health status. CASE REPORT: A 42-year old patient with severe COPD was admitted to the hospital. Despite maximal anti-obstructive therapy he required additional intravenous relief therapy and discharge was not possible. We treated this patient with a subcutaneous terbutaline pump for continuous and demand medication. We could show a significant decrease in additional intravenous medication, and the patient could leave the hospital. CONCLUSION: The use of terbutaline applied by a subcutaneous pump in addition to standard therapy may be helpful in severely ill patients suffering from COPD. This measure increased quality of life and shortened hospital stay
    Med Klin. 98(10).

Publication Stats

6 Citations
2.93 Total Impact Points

Institutions

  • 2003
    • Ruhr-Universität Bochum
      • Abteilung Paläontologie
      Bochum, North Rhine-Westphalia, Germany